3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Sarcoma
1
Neoplasms
1
Myelodysplastic Syndromes
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Hematologic Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Interventions
Azacitidine
38
Cytarabine
22
venetoclax
19
fludarabine phosphate
18
fludarabine
18
Cyclophosphamide
18
Peripheral Blood Stem Cell Transplantation
15
Tacrolimus
14
Filgrastim
13
Decitabine
13
Mycophenolic Acid
12
Busulfan
12
Whole-Body Irradiation
11
Melphalan
11
Methotrexate
10
Cyclosporine
10
Antilymphocyte Serum
8
Stem Cell Transplantation
7
Alemtuzumab
7
decitabine and cedazuridine drug combination
6
Granulocyte Colony-Stimulating Factor
6
Clofarabine
6
AP 1903 reagent
6
Thiotepa
5
Rituximab
5
Idarubicin
5
quizartinib
4
Tretinoin
4
Sirolimus
4
Radiotherapy
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Myelodysplastic Syndromes
×
bexmarilimab
×
Clear all
NCT05428969
2026-04-23
BEXMAB
Faron Pharmaceuticals Ltd
Phase 1/2
Active not recruiting
181 enrolled